IBM Story Is Underappreciated, Goldman Sachs Says Stock Can Re-Rate Higher
Goldman Sachs analyst James Schneider expressed views on International Business Machines Corporation‘s (NYSE:IBM) Investor ...
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...